We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ligand Pharmaceuticals Incorporated | NASDAQ:LGND | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.20 | 0.28% | 70.57 | 55.00 | 74.97 | 72.085 | 70.21 | 70.59 | 88,152 | 01:00:00 |
MARLBOROUGH, Mass., Jan. 18, 2017 /PRNewswire/ -- Lemelson Capital Management, LLC, a private investment management firm, today announced performance results for its flagship Amvona Fund, LP.
For 2016, The Amvona Fund returned 84.97 percent net of all fees and expenses, beating by 73 percent the benchmark S&P 500 Total Return Index[1], which returned 11.96 percent during this period. Since its September 2012 inception, The Amvona Fund, LP, has returned a compounded annualized rate or return of 23.81 percent net of all fees and expenses compared to 13.73 percent for the benchmark S&P 500 Total Return Index.
A few highlights for the firm and fund in 2016 include:
"While the performance of The Amvona Fund, LP, in 2016 was exceptional, investors should not expect this sort of return in the future," said Fr. Emmanuel Lemelson, Chief Investment Officer of Lemelson Capital Management. "Management's focus will remain on uncovering substantial price-value dislocations to continue to deliver a favorable compounded annualized rate of return to the partnership over the long run."
Further information, including an important notice and disclaimer regarding the fund's performance and this release, can be read here
About Lemelson Capital Management
Lemelson Capital Management, LLC, is a private investment management firm focused on deep value and special situation investments. Its flagship fund, The Amvona Fund, LP, has been named repeatedly among the world's top performing hedge funds since its September 2012 inception.
To see performance results by year, and read The Amvona Fund's annual and interim reports, visit www.lemelsoncapital.com
[1] The S&P 500 Total Return Index includes the reinvestment of dividends
For further information, please contact:
Media and Public Relations
Lemelson Capital Management, LLC
Telephone: 508-630-2281
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lemelson-capital-management-announces-2016-performance-results-for-the-amvona-fund-lp-300392758.html
SOURCE Lemelson Capital Management, LLC
Copyright 2017 PR Newswire
1 Year Ligand Pharmaceuticals Chart |
1 Month Ligand Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions